Bile acid synthesis disorders

Last updated
Bile acid synthesis disorders
Other namesBASDs

Bile acid synthesis disorders (BASDs) are rare metabolic disorders characterized by defects in the synthesis of bile acids, which are crucial for cholesterol breakdown and the absorption of fats and fat-soluble vitamins. [1] [2] These disorders can lead to the accumulation of abnormal bile acids and intermediary metabolites, causing damage to various organs. [1]

Contents

Classification

Bile Acid Synthesis Disorders are classified into two main categories: primary and secondary disorders, each with distinct characteristics and underlying causes.[ citation needed ]

Primary Bile acid synthesis disorders

Primary BASDs result from genetic mutations affecting enzyme directly involved in the biosynthetic pathways of bile acids. [2] [3] [4] These disorders are typically autosomal recessive and lead to the production of atypical bile acids, causing liver dysfunction and other systemic effects. [1] [2] Some of the key primary BASDs include:

Secondary Bile acid synthesis disorders

Secondary BASDs are not caused by defects in bile acid synthesis enzymes but result from issues related to bile acid transport, metabolism, or supply of cholesterol precursors. [2] [1] These can be due to:

Bile acid transporter defects

Bile acid transporter defects occur when mutations affect the proteins responsible for transporting bile acids across cellular membranes, leading to their accumulation or improper reabsorption. These defects can result in cholestasis, liver injury, and systemic complications.[ citation needed ] Examples of bile acid transporter defects include:

Cholesterol supply disorders

Cholesterol supply disorders are secondary conditions that limit the availability of cholesterol for bile acid synthesis, indirectly affecting bile acid production. [2]

Symptoms and signs

Bile Acid Synthesis Disorders present a range of symptoms, often beginning in infancy or early childhood. Jaundice, characterized by yellowing of the skin and eyes, is a common early sign. [8] [9] Growth deficiencies are prevalent, with affected individuals often failing to meet weight and height milestones due to malabsorption of fats and fat-soluble vitamins like A, D, E, and K. [1] [8] [9] This can lead to Vitamin deficiencies, resulting in vision problems (vitamin A), rickets (vitamin D), neurological issues (vitamin E), and blood coagulation problems (vitamin K). [8] Liver-related symptoms include hepatomegaly (enlarged liver) and splenomegaly (enlarged spleen), with elevated liver enzymes indicating liver dysfunction. [9] Patients may experience cholestasis, a condition where bile flow is interrupted, leading to pale stools, dark urine, and sometimes severe itching. [10] Steatorrhea, or excess fat in stools, is another symptom due to impaired fat digestion. [1] [3] In severe cases, BASDs can progress to liver failure if untreated. The variability in symptom onset and severity depends on the specific genetic defect involved. [3]

Diagnosis

Diagnosing Bile Acid Synthesis Disorders (BASDs) requires a comprehensive approach due to their rarity and symptom overlap with other liver diseases. Physicians begin by suspecting BASDs in infants or children presenting with jaundice, unexplained liver disease, or fat-soluble vitamin deficiencies. [1] Initial laboratory tests often include measuring serum bile acids. [11]

Advanced diagnostic techniques involve mass spectrometry, Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and electrospray ionization-tandem mass spectrometry (ESI-MS/MS), to analyze bile acid profiles in urine and blood. [12] [5] These methods identify atypical bile acids and intermediates that accumulate due to enzyme deficiencies. Fast atom bombardment-mass spectrometry (FAB-MS) is another technique used to detect specific bile acid patterns indicative of BASDs. [11] [3] Genetic testing confirms the diagnosis by identifying mutations in genes responsible for bile acid synthesis enzymes. [13]

Treatment

Treatment for BASDs primarily involves oral bile acid replacement therapy. Cholic acid, approved in 2015, is the standard treatment for patients with single enzyme defects and peroxisomal disorders. [10] This therapy compensates for the lack of primary bile acids, restoring normal liver function and improving symptoms like jaundice and malabsorption. [14] [3]

In some cases, ursodeoxycholic acid may be used alongside cholic acid to enhance bile flow, although it is ineffective as a sole treatment. The dosage of cholic acid is carefully monitored to suppress abnormal metabolite production and improve liver biochemistry. [3] [14]

For patients unresponsive to medical therapy or with advanced liver disease, liver transplantation may be necessary. Early intervention with cholic acid has been shown to prevent progression to liver failure and improve long-term health outcomes, allowing many patients to lead normal lives into adulthood. [10]

Epidemiology

Bile Acid Synthesis Disorders are rare conditions with limited epidemiological data available. The overall prevalence of BASDs is estimated to be between 1-9 cases per 1,000,000 people in the general population. [7] However, this figure likely underestimates the true prevalence due to underdiagnosis and lack of awareness among healthcare providers.

BASDs are thought to account for approximately 1-2% of all childhood cholestatic disorders. [1] In Europe, a study found a minimum estimated combined prevalence of 1.13 cases per 10 million people for two common types of BASDs

These disorders affect males and females equally and can occur in individuals of any race or ethnicity. [1] The age of onset varies, with presentations possible in infancy, childhood, or adulthood, depending on the specific type of BASD. [7]

Related Research Articles

<span class="mw-page-title-main">Methylmalonic acidemias</span> Medical condition

Methylmalonic acidemias, also called methylmalonic acidurias, are a group of inherited metabolic disorders, that prevent the body from properly breaking down proteins and fats. This leads to a buildup of a toxic level of methylmalonic acid in body liquids and tissues. Due to the disturbed branched-chain amino acids (BCAA) metabolism, they are among the classical organic acidemias.

<span class="mw-page-title-main">Chylomicron</span> One of the five major groups of lipoprotein

Chylomicrons, also known as ultra low-density lipoproteins (ULDL), are lipoprotein particles that consist of triglycerides (85–92%), phospholipids (6–12%), cholesterol (1–3%), and proteins (1–2%). They transport dietary lipids, such as fats and cholesterol, from the intestines to other locations in the body, within the water-based solution of the bloodstream. ULDLs are one of the five major groups lipoproteins are divided into based on their density. A protein specific to chylomicrons is ApoB48.

<span class="mw-page-title-main">Alagille syndrome</span> Medical condition

Alagille syndrome (ALGS) is a genetic disorder that affects primarily the liver and the heart. Problems associated with the disorder generally become evident in infancy or early childhood. The disorder is inherited in an autosomal dominant pattern, and the estimated prevalence of Alagille syndrome is 1 in every 30,000 to 1 in every 40,000 live births. It is named after the French pediatrician Daniel Alagille, who first described the condition in 1969. Children with Alagille syndrome live to the age of 18 in about 90% of the cases.

<span class="mw-page-title-main">Smith–Lemli–Opitz syndrome</span> Recessive genetic condition

Smith–Lemli–Opitz syndrome is an inborn error of cholesterol synthesis. It is an autosomal recessive, multiple malformation syndrome caused by a mutation in the enzyme 7-Dehydrocholesterol reductase encoded by the DHCR7 gene. It causes a broad spectrum of effects, ranging from mild intellectual disability and behavioural problems to lethal malformations.

<span class="mw-page-title-main">Citrullinemia</span> Medical condition

Citrullinemia is an autosomal recessive urea cycle disorder that causes ammonia and other toxic substances to accumulate in the blood.

<span class="mw-page-title-main">Cholestasis</span> Medical condition

Cholestasis is a condition where the flow of bile from the liver to the duodenum is impaired. The two basic distinctions are:

<span class="mw-page-title-main">Cholic acid</span> Main bile acid

Cholic acid, also known as 3α,7α,12α-trihydroxy-5β-cholan-24-oic acid is a primary bile acid that is insoluble in water, it is a white crystalline substance. Salts of cholic acid are called cholates. Cholic acid, along with chenodeoxycholic acid, is one of the two major bile acids produced by the liver, where it is synthesized from cholesterol. These two major bile acids are roughly equal in concentration in humans. Derivatives are made from cholyl-CoA, which exchanges its CoA with either glycine, or taurine, yielding glycocholic and taurocholic acid, respectively.

<span class="mw-page-title-main">Bile acid</span> Steroid acid found predominantly in the bile of mammals and other vertebrates

Bile acids are steroid acids found predominantly in the bile of mammals and other vertebrates. Diverse bile acids are synthesized in the liver. Bile acids are conjugated with taurine or glycine residues to give anions called bile salts.

<span class="mw-page-title-main">Methylmalonyl-CoA mutase deficiency</span> Medical condition

Methylmalonyl-CoA mutase is a mitochondrial homodimer apoenzyme that focuses on the catalysis of methylmalonyl CoA to succinyl CoA. The enzyme is bound to adenosylcobalamin, a hormonal derivative of vitamin B12 in order to function. Methylmalonyl-CoA mutase deficiency is caused by genetic defect in the MUT gene responsible for encoding the enzyme. Deficiency in this enzyme accounts for 60% of the cases of methylmalonic acidemia.

Progressive familial intrahepatic cholestasis (PFIC) is a group of familial cholestatic conditions caused by defects in biliary epithelial transporters. The clinical presentation usually occurs first in childhood with progressive cholestasis. This usually leads to failure to thrive, cirrhosis, and the need for liver transplantation.

Neonatal cholestasis refers to elevated levels of conjugated bilirubin identified in newborn infants within the first few months of life. Conjugated hyperbilirubinemia is clinically defined as >20% of total serum bilirubin or conjugated bilirubin concentration greater than 1.0 mg/dL regardless of total serum bilirubin concentration. The differential diagnosis for neonatal cholestasis can vary extensively. However, the underlying disease pathology is caused by improper transport and/or defects in excretion of bile from hepatocytes leading to an accumulation of conjugated bilirubin in the body. Generally, symptoms associated with neonatal cholestasis can vary based on the underlying cause of the disease. However, most infants affected will present with jaundice, scleral icterus, failure to thrive, acholic or pale stools, and dark urine.

<span class="mw-page-title-main">Sitosterolemia</span> Genetically-inherited lipid metabolic disorder

Sitosterolemia, also known as phytosterolemia, is a rare autosomal recessively inherited lipid metabolic disorder. It is characterized by hyperabsorption and decreased biliary excretion of dietary sterols. Healthy persons absorb only about 5% of dietary plant sterols, but sitosterolemia patients absorb 15% to 60% of ingested sitosterol without excreting much into the bile. The phytosterol campesterol is more readily absorbed than sitosterol.

<span class="mw-page-title-main">Cerebrotendinous xanthomatosis</span> Genetic bile acid metabolism disorder

Cerebrotendinous xanthomatosis (CTX), also called cerebral cholesterosis, is a rare inborn bile acid metabolism disorder caused by autosomal-recessive mutations in the CYP27A1 gene. CTX is characterized by a wide range of symptoms, including neurological and non-neurological issues.

Acid lipase disease or deficiency is a name used to describe two related disorders of fatty acid metabolism. Acid lipase disease occurs when the enzyme lysosomal acid lipase that is needed to break down certain fats that are normally digested by the body is lacking or missing. This results in the toxic buildup of these fats in the body's cells and tissues. These fatty substances, called lipids, include waxes, oils, and cholesterol.Three rare lipid storage diseases are caused by the deficiency of the enzyme lysosomal acid lipase:

<span class="mw-page-title-main">Cholesterol 7 alpha-hydroxylase</span> Protein-coding gene in the species Homo sapiens

Cholesterol 7 alpha-hydroxylase also known as cholesterol 7-alpha-monooxygenase or cytochrome P450 7A1 (CYP7A1) is an enzyme that in humans is encoded by the CYP7A1 gene which has an important role in cholesterol metabolism. It is a cytochrome P450 enzyme, which belongs to the oxidoreductase class, and converts cholesterol to 7-alpha-hydroxycholesterol, the first and rate limiting step in bile acid synthesis.

<span class="mw-page-title-main">Acetoacetyl-CoA</span> Chemical compound

Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway, which is essential for cholesterol biosynthesis. It also takes a similar role in the ketone bodies synthesis (ketogenesis) pathway of the liver. In the ketone bodies digestion pathway, it is no longer associated with having HMG-CoA as a product or as a reactant.

D-Bifunctional protein deficiency is an autosomal recessive peroxisomal fatty acid oxidation disorder. Peroxisomal disorders are usually caused by a combination of peroxisomal assembly defects or by deficiencies of specific peroxisomal enzymes. The peroxisome is an organelle in the cell similar to the lysosome that functions to detoxify the cell. Peroxisomes contain many different enzymes, such as catalase, and their main function is to neutralize free radicals and detoxify drugs. For this reason peroxisomes are ubiquitous in the liver and kidney. D-BP deficiency is the most severe peroxisomal disorder, often resembling Zellweger syndrome.

In enzymology, a cholest-5-ene-3β,7α-diol 3β-dehydrogenase (EC 1.1.1.181) is an enzyme that catalyzes the chemical reaction

<span class="mw-page-title-main">Chylomicron retention disease</span> Medical condition

Chylomicron retention disease is a disorder of fat absorption. It is associated with SAR1B. Mutations in SAR1B prevent the release of chylomicrons in the circulation which leads to nutritional and developmental problems. It is a rare autosomal recessive disorder with around 40 cases reported worldwide. Since the disease allele is recessive, parents usually do not show symptoms.

<span class="mw-page-title-main">Lysosomal acid lipase deficiency</span> Medical condition

Lysosomal acid lipase deficiency or Wolman Disease, is an autosomal recessive inborn error of metabolism that results in the body not producing enough active lysosomal acid lipase (LAL) enzyme. This enzyme plays an important role in breaking down fatty material in the body. Infants, children and adults that have LAL deficiency experience a range of serious health problems. The lack of the LAL enzyme can lead to a build-up of fatty material in a number of body organs including the liver, spleen, gut, in the wall of blood vessels and other important organs.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Bile Acid Synthesis Disorders - Symptoms, Causes, Treatment | NORD". rarediseases.org. Archived from the original on 2024-12-13. Retrieved 2024-12-13.
  2. 1 2 3 4 5 "Overview of bile acid sythesis disorders". Rarecholestasis. Retrieved 2024-12-13.
  3. 1 2 3 4 5 6 7 Sundaram, S. S.; Bove, K. E.; Lovell, M. A.; Sokol, R. J. (24 June 2008). "Mechanisms of Disease: inborn errors of bile acid synthesis". Nature Clinical Practice. Gastroenterology & Hepatology. 5 (8): 456–468. doi:10.1038/ncpgasthep1179. PMC   3888787 . PMID   18577977.
  4. "Congenital bile acid synthesis defect type 1: MedlinePlus Genetics". medlineplus.gov. Archived from the original on 2024-12-13. Retrieved 2024-12-13.
  5. 1 2 Haas, D.; Gan-Schreier, H.; Langhans, C. D.; Rohrer, T.; Engelmann, G.; Heverin, M.; Russell, D. W.; Clayton, P. T.; Hoffmann, G. F.; Okun, J. G. (14 March 2012). "Differential diagnosis in patients with suspected bile acid synthesis defects". World Journal of Gastroenterology. 18 (10): 1067–1076. doi: 10.3748/wjg.v18.i10.1067 . PMC   3296980 . PMID   22416181.
  6. "Bile Acid Synthesis Disorders" (PDF). CincinnatiChildren's. Archived (PDF) from the original on 13 December 2024. Retrieved 13 December 2024.
  7. 1 2 3 "Orphanet: Disorder of bile acid synthesis". www.orpha.net. Archived from the original on 2024-12-13. Retrieved 2024-12-13.
  8. 1 2 3 Bile synthesis disorders (NORD): Video, Causes, & Meaning | Osmosis. Archived from the original on 2024-12-13. Retrieved 2024-12-13 via www.osmosis.org.
  9. 1 2 3 "What is bile acid synthesis disorders (BASD)? | CHOLBAM®". CHOLBAM® (cholic acid) capsules. Retrieved 2024-12-13.
  10. 1 2 3 Staff, CheckRare (2017-11-02). "Bile Acid Synthesis Disorders". CheckRare. Archived from the original on 2024-12-21. Retrieved 2024-12-13.
  11. 1 2 "Bile Acid Synthesis and Metabolism Defects Information for Physicians". childrennetwork.org. Archived from the original on 2024-12-13. Retrieved 2024-12-13.
  12. Espinosa-Escudero, Ricardo; Herraez, Elisa; Sanchez-Martin, Anabel; Sanchon-Sanchez, Paula; Marin, Jose J. G.; Monte, Maria J. (2022-12-07). "Cholestasis associated to inborn errors in bile acid synthesis". Exploration of Digestive Diseases. 1 (3): 137–153. doi:10.37349/edd.2022.00010. ISSN   2833-6321. Archived from the original on 2024-05-14. Retrieved 2024-12-13.
  13. Mahjoub, Fatemeh Elham; Motamed, Farzaneh; Niknejad, Nakisa; Farahmand, Fatemeh; Hadipour, Fatemeh; Asili, Pooria (2023). "Bile Acid Synthesis Disorder, the First Reported Case from Iran, (Proven by Genetic Study), How the Unavailability of Drug Affected the Course of Treatment". Iranian Journal of Pediatrics. 33 (3). doi:10.5812/ijp-133741. ISSN   2008-2150.
  14. 1 2 Gonzales, E.; Matarazzo, L.; Franchi-Abella, S.; Dabadie, A.; Cohen, J.; Habes, D.; Hillaire, S.; Guettier, C.; Taburet, A. M.; Myara, A.; Jacquemin, E. (29 October 2018). "Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood". Orphanet Journal of Rare Diseases. 13 (1): 190. doi: 10.1186/s13023-018-0920-5 . PMC   6206929 . PMID   30373615.
  15. 1 2 Jahnel, Jörg; Zöhrer, Evelyn; Fischler, Björn; D'Antiga, Lorenzo; Debray, Dominique; Dezsofi, Antal; Haas, Dorothea; Hadzic, Nedim; Jacquemin, Emmanuel; Lamireau, Thierry; Maggiore, Giuseppe; McKiernan, Pat J.; Calvo, Pier L.; Verkade, Henkjan J.; Hierro, Loreto (June 2017). "Attempt to Determine the Prevalence of Two Inborn Errors of Primary Bile Acid Synthesis: Results of a European Survey". Journal of Pediatric Gastroenterology and Nutrition. 64 (6): 864–868. doi:10.1097/MPG.0000000000001546. ISSN   1536-4801. PMID   28267072. Archived from the original on 2023-05-22. Retrieved 2024-12-13 via PubMed.